/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
According to THE SAGE GROUP, Critical Limb Ischemia (CLI) is a Major and Growing Problem
BEAUFORT, S.C.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CLI&src=ctag” target=”_blank”gt;$CLIlt;/agt; lt;a href=”https://twitter.com/hashtag/CLI?src=hash” target=”_blank”gt;#CLIlt;/agt;–At the 15th annual Critical Limb Ischemia Session of the New
Cardiovascular Horizons (NCVH) meeting in New Orleans, Mary L. Yost,
President of THE SAGE GROUP, spoke on “The Scope of Critical Limb
Ischemia (CLI).”
“Between 2.0 and 3.4 million people currently suffer from CLI in the
U.S.,” stated Yost. “By 2030 CLI is expected to increase to 4.7 million
due to the aging population. However, if the prevalence of diabetes
continues to increase at the same pace as the last 20 years, this
estimate will be conservative.”
CLI, or ‘end-stage’ peripheral artery disease (PAD), is characterized by
rest pain, ulcers and gangrene.
Commenting on disease costs, Yost stated, “CLI is expensive to treat,
accounting for the majority of PAD costs. CLI is more costly to treat
than less severe disease, which combined with the increasing number of
patients treated, has resulted in CLI becoming a major economic burden.
These costs are especially significant for taxpayers because Medicare
pays 73% of the CLI bill.”
“Costs increase with disease severity,” Yost explained. “Rutherford 6
patients with gangrene cost more to treat than Rutherford 4 and 5 with
rest pain and ulcers respectively, which in turn, cost more than
intermittent claudication (IC) patients. CLI expenses are driven up by
multiple factors including unplanned readmissions and undertreatment of
risk factors. Suboptimal medical management increases morbidity and
mortality leading to expensive diabetic and cardiovascular
hospitalizations.”
“Amazingly, revascularization is underutilized in CLI patients, even
versus IC patients,” she declared. Between 25%-33% of CLI patients are
treated with primary amputation, which is more expensive than
revascularization. Higher hospital costs of major amputation reflect
more frequent and expensive complications, in-hospital mortality and
revision procedures,” she stated.
“The tragedy is that earlier diagnosis of CLI and appropriate treatment
could save lives and limbs,” concluded Ms. Yost. “This would also save a
tremendous amount of money.”
Additional information on NCVH and the agenda can be found at: https://www.ncvh.org/meetings/annual-conference-2019/agenda.php.
THE SAGE GROUP, a research and consulting company, specializes in
peripheral vascular disease in the lower limbs, specifically chronic
venous disease (CVD), PAD, CLI, IC, diabetic foot ulcers (DFU) and the
costs and consequences of amputation.
Additional information: www.thesagegroup.us.
Contacts
THE SAGE GROUP
Mary Yost, (404) 520-6652
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Humboldt
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia
SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.
The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.
Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.
“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”
Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”
About Humboldt Seed Company
Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.
For more information visit https://humboldtseedcompany.com/.
About Apollo Green
Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics.
For more information visit https://apollogreen.com/.
Media contact
Jaana Prall
[email protected]
Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE2 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace